Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) from a sell rating to a hold rating in a research note published on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Biodexa Pharmaceuticals currently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 2.1%

BDRX opened at $0.70 on Friday. The company has a fifty day simple moving average of $1.40 and a 200 day simple moving average of $4.06. Biodexa Pharmaceuticals has a twelve month low of $0.68 and a twelve month high of $19.40.

Biodexa Pharmaceuticals’s stock is set to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 3rd.

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest position. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.